Navigation Links
Cell Therapeutics, Inc. Announces Closing of Registered Offering of $30 Million of Preferred Stock and Warrants
Date:8/21/2009

prospectus supplement and accompanying prospectus may be obtained directly from the Company by contacting the Company at the following address: Cell Therapeutics, Inc., 501 Elliott Avenue West, Suite 400, Seattle, Washington 98119. This announcement is neither an offer to sell nor a solicitation of an offer to buy any of our shares of Series 2 Preferred Stock or warrants. No offer, solicitation or sale will be made in any jurisdiction in which such offer, solicitation or sale is unlawful.

This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results and the trading prices of the Company's securities. The risks and uncertainties include the risk that the investors might not exercise their warrants, the Company might not be able to continue to raise additional capital as needed to fund its operations, the Company's intentions regarding the use of proceeds, and other risk factors listed or described from time to time in the Company's filings with the SEC, including, without limitation, its most recent filings on Forms 10-K, 10-Q and 8-K. Except as required by law, the Company does not intend to update any of the statements in this press release upon further developments.

    Media Contact:

    Dan Eramian
    T: 206.272.4343
    C: 206.854.1200
    E: media@ctiseattle.com
    www.CellTherapeutics.com/press_room

    Investors Contact:

    Ed Bell
    T: 206.272.4345

    Lindsey Jesch Logan
    T: 206.272.4347
    F: 206.272.4434
    E: invest@ctiseattle.com
    www.CellTherapeutics.com/investors


'/>"/>
SOURCE Cell Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Cell Therapeutics, Inc. Announces Institutional Investor Purchases $30 Million of Preferred Stock and Warrants
2. Oxygen Biotherapeutics, Inc. Files 10-K for Fiscal Year Ended April 30, 2009
3. Nile Therapeutics, Inc. Announces Dosing of First Patient in Phase 2 Study of CD-NP for the Treatment of Acute Heart Failure
4. Cell Therapeutics, Inc. Announces Exercise of Overallotment
5. Cell Therapeutics, Inc. Announces Pricing of Public Offering of Common Stock and Warrants
6. Nile Therapeutics, Inc. Completes $3.4 Million Private Placement
7. Oxygen Biotherapeutics, Inc. Announces Closing of Private Placement Financing Agreement
8. Nile Therapeutics, Inc. To Raise $3.4 Million in Private Placement
9. Intarcia Therapeutics, Inc. Presents ITCA 650 Phase 1b Study Results as a Late-Breaker at the American Diabetes Association 69th Scientific Sessions
10. Intarcia Therapeutics, Inc. Announces Acceptance of ITCA 650 Phase 1b Study for Late-Breaker Presentation at the American Diabetes Association 69th Scientific Sessions
11. Prospect Therapeutics, Inc.s GCS-100 Inhibited Blood Vessel Formation in a Variety of Cancer Models
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... ... July 29, 2015 , ... Strong Animals™ announced today that ... dairy operation and presented at the ADSA-ASAS Joint Annual Meeting held July 12-16 in ... dairy cows and increased milk fat content. Also, feed containing Stay Strong™ for Dairy ...
(Date:7/28/2015)... Nev. , July 28, 2015  PDL BioPharma, ... today announced that the Company will release its second ... 30, 2015, on Wednesday, August 5, 2015, after market ... webcast that day at 4:30 p.m. Eastern Time to ... the call will be available via the webcast link ...
(Date:7/28/2015)... Mass. , July 28, 2015 ... measuring cell metabolism, is the provider of XF ... across all disease research areas. As the links ... exploration into cell metabolism is escalating rapidly.   ... published by the Nature Publishing Group (NPG) featuring ...
(Date:7/28/2015)... 21, 2015 Research ... addition of the "Analysis of the Global ... offering. Globally, flow cytometry remains a ... proliferation, cancer, and stem cells. But the market ... because of demand from underdeveloped nations to quantitate ...
Breaking Biology Technology:Strong Animals™ Announces South Dakota State University Research Demonstrates Stay Strong™ for Dairy Cows Improves Performance and Feed Stability 2PDL BioPharma to Announce Second Quarter 2015 Financial Results on August 5, 2015 2XF Technology Used to Demonstrate Feasibility of Stem Cell Regenerative Technique 2XF Technology Used to Demonstrate Feasibility of Stem Cell Regenerative Technique 3Analysis of the Global Flow Cytometry Market 2012-2018 with a 2014 Base Year and a 2015-2018 Forecast Period 2
... SAN FRANCISCO, Nov. 2, 2011 Jennerex, Inc., a ... commercialization of first-in-class targeted oncolytic products for cancer, today ... clinical trial in advanced liver cancer patients will be ... Annual Meeting of the American Association for the Study ...
... a premature ageing disease that affects children causing them to ... rate. The study is the first to outline how ... could provide a model for understanding processes that cause us ... such as reducing degeneration of some tissues in older age, ...
... World, Paul Blom and Ton van Mol from the ... thin, flexible sheets of organic light-emitting diodes (OLEDs) using ... bendable materials could oust the conventional light bulb and ... for everything from lighting tiles and strips in homes ...
Cached Biology Technology:Jennerex to Present Final Survival Data From Randomized Phase 2 Clinical Trial of JX-594 in Advanced Liver Cancer at American Association for the Study of Liver Diseases Annual Meeting 2Jennerex to Present Final Survival Data From Randomized Phase 2 Clinical Trial of JX-594 in Advanced Liver Cancer at American Association for the Study of Liver Diseases Annual Meeting 3Jennerex to Present Final Survival Data From Randomized Phase 2 Clinical Trial of JX-594 in Advanced Liver Cancer at American Association for the Study of Liver Diseases Annual Meeting 4Cellular repair could reduce premature aging 2Cellular repair could reduce premature aging 3Researchers roll out a new form of lighting 2
(Date:7/13/2015)... 2015 Synaptics Inc. (NASDAQ: SYNA ... today announced sampling of ClearPad ® 4300, ... (TDDI) product targeting smartphones and tablets. This new ... , best-in-class touch controller IP and systems ... in the company,s Japan Design Center. TDDI enables ...
(Date:7/9/2015)... SAN JOSE, Calif. , July 9, 2015 /PRNewswire/ ... human interface solutions, announced today that it will report ... 2015 on Thursday, July 30, 2015 after the close ... call for analysts and investors at 2:00 p.m. PT ... information.    To participate on the live ...
(Date:7/9/2015)... 2015  Unchained Labs just can,t get enough ... Avid Nano. Avid Nano designs, develops and manufactures ... Also today, Unchained Labs UNcaged the ... use protein sizing system. The pUNk is a ... size, size distribution, aggregation population and molecular weight. ...
Breaking Biology News(10 mins):Synaptics Announces Sampling of Second Generation TDDI Solutions 2Synaptics Announces Sampling of Second Generation TDDI Solutions 3Synaptics to Report Fourth Quarter, Fiscal Year 2015 Results on July 30 2Unchained Labs just can't get enough, acquires Avid Nano, rocks out the new pUNk! 2
... California pistachios took center stage at this year,s American ... (FNCE), the industry,s premier conference where thousands of registered ... emerging health trends. Pistachios led with ... of mindful eating and, for the first time ever, ...
... A monoclonal antibody targeting a well known cell surface ... aggressive form of the disease that did not respond ... with the UCLA Department of Urology and UCLA,s Jonsson ... the protein, N-cadherin, is up regulated or turned on ...
... found that women who receive silicone implants after a double ... receive saline implants. Published early online in CANCER , ... may help physicians and breast cancer survivors as they together ... have one or both of their breasts removed as a ...
Cached Biology News:California pistachios: Dietitian and Mother Nature approved 2California pistachios: Dietitian and Mother Nature approved 3UCLA researchers discover a potential target for therapy for patients with a deadly prostate cancer 2UCLA researchers discover a potential target for therapy for patients with a deadly prostate cancer 3Breast cancer patients prefer silicone over saline implants after mastectomy 2
... polyclonal to Taura Syndrome Virus ... for all tested applications). ... peptide: VTNSEGSTIL MNDIPITNQN VVLSKNVTDN LFEVQDQALI ... to N terminal amino acids ...
JAB1 Immunogen: Synthetic peptide, conjugated to KLH, corresponding to residues S(201) E Y Q T I P L N K I E D F G V(216) of human JAB1. The sequence is identical in mouse and rat. Storage: -...
Anti-Mouse Ly 6C.2 , Ascites (Clone 5075-3.6) (mouse IgG2b)...
BDFastImmune? IFN-gamma /CD69/CD4/CD3 Storage Temperature: Refrigerate(2 to 8C)...
Biology Products: